Anaphylaxis News
-
Intrommune Therapeutics Completes Enrollment in the Phase 1 OMEGA Study for Peanut Allergy
Observed only mild and transient adverse events, with no use of emergency epinephrine Observed 98.4% patient compliance to date with novel OMIT therapeutic modality Safely started patients on dose 4, potentially reducing the time to reach maintenance by several weeks NEW YORK, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology ...
-
VBI Vaccines Secures $100 Million Debt Facility From K2 HealthVentures
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced it has entered into a refinanced and upsized debt facility of up to $100 million with its existing lender, K2 HealthVentures (K2HV), a healthcare-focused specialty finance company. Under the terms of the agreement, $50 million is ...
-
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (Valneva) and VBI Vaccines Inc. (Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe. Under the terms of the agreement, specialty vaccine company Valneva will promote ...
-
VBI Vaccines Announces Appointment of John Dillman as Chief Commercial Officer
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of ...
-
VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study (PROTECT) of the Company’s 3-antigen prophylactic hepatitis B (HBV) vaccine, were presented in an oral presentation at The ...
-
Intrommune Announces Expanded Scope of Phase 1 OMEGA Study in Adults with Peanut Allergy
NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced an amendment to its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy. The amendment increases the study duration for patients to 48 ...
-
Intrommune Therapeutics Names Nandini Murthy as Head of Regulatory
NEW YORK, June 01, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the addition of Nandini Murthy as Head of Regulatory. “Ms. Murthy has proven to be an invaluable asset to Intrommune since joining the organization as a consultant ...
-
VBI Vaccines Announces Abstract Accepted for Oral Presentation at EASL 2022
VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that an abstract highlighting long-term durability of immune response data following vaccination with VBI’s 3-antigen hepatitis B (HBV) vaccine has been accepted for oral presentation at The International Liver ...
-
The Essential Guide to Food Allergies
Food Allergy Research and Education (FARE) has established that more than 32 million people in the US are victims of food allergy. Almost 8% of children with a food allergy are less than 5 years old and overall 4% of adults suffer from food allergies. Research conducted by NIH shows that more than 3.24% people in France have different types of food allergies. The study also shows that there is an ...
-
INT301 Continues to Meet Safety Goals in Phase 1 OMEGA Study in Adults with Peanut Allergy While Reaching Phase 2 Target Maintenance Dose
NEW YORK, April 06, 2022 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, today announced that its ongoing Phase 1 OMEGA Clinical Study of INT301 in adult patients with peanut allergy has been amended to allow determination of the Maximum Tolerated Dose ...
-
Blue Earth Diagnostics Highlights Axumin (Fluciclovine F 18) Presentation at Upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO)
Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, today announced a presentation on Axumin® (fluciclovine F 18) at the upcoming 22nd Annual Scientific Meeting in Urologic Oncology (SUO), to be held in Orlando, Fla., from December 1 to 3, 2021. The Society of Urologic Oncology sponsors this highly ...
-
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the promotion of Sergi Trilla, MD to become Director of Corporate Strategy & Partnerships. “Dr. Trilla has proven to be an invaluable asset to Intrommune since he ...
-
Intrommune Therapeutics Launches #PeanutAllergyStrong
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced the launch of its #PeanutAllergyStrong patient engagement campaign. “Supporting peanut allergy patients and their loved ones has always been the central mission at ...
-
Intrommune Therapeutics to Present at BIO Digital 2021
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies, announced today that it will be presenting at BIO Digital 2021. The event will be live June 10-11 & 14-18, 2021. Michael Nelson, JD, Co-Founder and CEO will provide an overview of ...
-
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data from the Phase 2 BLAZE-4 Trial Evaluating Bamlanivimab with VIR-7831 in Low-Risk Adults with COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced topline data from the expanded Phase 2 BLAZE-4 trial studying low-risk adult patients with mild to moderate COVID-19. Results showed that investigational bamlanivimab (LY-CoV555) 700 mg co-administered with VIR-7831 (also known as GSK4182136) 500 mg demonstrated a 70 ...
-
Transcript: CDC Update on COVID-19
OPERATOR: AT THIS TIME, ALL PARTICIPANTS ARE ON LISTEN-ONLY MODE. SO, IF YOU WOULD LIKE TO ASK A QUESTION, PLEASE PRESS STAR AND THEN ONE. TODAY’S CONFERENCE IS BEING RECORDED. IF YOU HAVE ANY OBJECTIONS, YOU MAY DISCONNECT AT THIS TIME. AND NOW I WOULD LIKE TO TURN THE MEETING OVER TO MR. BENJAMIN HAYNES. SIR YOU MAY BEGIN. HAYNES: THANK YOU, BRITTANY. AND THANKS TO EVERYONE ...
-
FDA Clears First Blood Test for Identifying a Novel Allergic Sensitization to Red Meat
ImmunoCAP Specific IgE alpha-Gal Allergen Component test has been cleared by the U.S. Food & Drug Administration (FDA) for in vitro diagnostic use. Test results can aid specialists and other healthcare providers as they diagnose a patient's sensitization to the alpha-Gal carbohydrate found in mammalian (red) meat and assess his or her risk for an anaphylactic reaction. According to the ...
-
New Blood Test Helps Clinicians Pinpoint A Potentially Life-Threatening Sensitization to Insect Stings
ImmunoCAP Specific IgE Stinging Insect Allergen Components have been cleared by the U.S. Food & Drug Administration (FDA) for in vitro diagnostic use. Results from these component tests can act as a diagnostic aid to help specialists and other healthcare providers discriminate between true sensitization and cross reactivity, identify culprit insect(s) in patients with inconclusive patient ...
-
TargetSolutions’ EMS Continuing Education Course Examines Emergency Care for Allergies and Anaphylaxis
TargetSolutions’ EMS Allergies and Anaphylaxis Basic training course covers the topics of allergy-related incidents and the appropriate care needed in such situations. Allergic reactions can develop as simple irritations, but quickly mobilize into life-threatening emergencies. EMS responders are tasked with determining the severity of the condition as emergency medical care and rapid ...
-
Shimadzu’s New Aggregation Analysis System for Biopharmaceuticals Enables Real-time Quantitative Analysis of Sub-Visible Particles
Shimadzu Scientific Instruments has introduced an Aggregates Sizer Aggregation Analysis System, the first commercially available tool to provide real-time quantitative evaluation of 100nm to 10μm sub-visible particle (SVP) aggregates. By screening and identifying aggregation-prone proteins in early stage drug development, manufacturers can save time and reduce costs. Sub-visible particle ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you